Cargando…

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia

BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm classified in the myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) category. Molecular abnormalities are reported in about 90 % of patients with CMML. ASXL1 and SETBP1 mutations, but not TET2 or SFRS2 mutations ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Yajuan, Tong, Hongyan, Du, Xin, Li, Bing, Gale, Robert Peter, Qin, Tiejun, Liu, Jinqin, Xu, Zefeng, Zhang, Yue, Huang, Gang, Jin, Jie, Fang, Liwei, Zhang, Hongli, Pan, Lijuan, Hu, Naibo, Qu, Shiqiang, Xiao, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445804/ https://www.ncbi.nlm.nih.gov/pubmed/26019984 http://dx.doi.org/10.1186/s40164-015-0009-y

Ejemplares similares

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia
por: Ouyang, Yuan, et al.
Publicado: (2017)

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant
por: Qu, Shiqiang, et al.
Publicado: (2022)

SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS
por: Inoue, Daichi, et al.
Publicado: (2014)

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
por: Yan, Xin, et al.
Publicado: (2023)

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022)

Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia
por: Johnson, Steven M., et al.
Publicado: (2019)

P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA
por: Wang, Yu-Hung, et al.
Publicado: (2023)

CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia
por: Qian, Yi, et al.
Publicado: (2021)

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation
por: Saika, Makoto, et al.
Publicado: (2018)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes
por: Wang, Jingya, et al.
Publicado: (2016)

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
por: Luo, Xueping, et al.
Publicado: (2018)

A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
por: Feng, Gege, et al.
Publicado: (2016)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia
por: Hu, WangQiang, et al.
Publicado: (2015)

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
por: Kim, Hyun-Young, et al.
Publicado: (2018)

Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group
por: Bresolin, Silvia, et al.
Publicado: (2016)

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis
por: Shou, Li-Hong, et al.
Publicado: (2017)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Alteration of the SETBP1 Gene and Splicing Pathway Genes SF3B1, U2AF1, and SRSF2 in Childhood Acute Myeloid Leukemia
por: Choi, Hyun-Woo, et al.
Publicado: (2015)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis
por: Wang, Hongdan, et al.
Publicado: (2023)

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
por: Binder, Moritz, et al.
Publicado: (2022)

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Binder, Moritz, et al.
Publicado: (2023)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017)

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
por: Perez Botero, J, et al.
Publicado: (2015)

Somatic SETBP1 mutations in myeloid malignancies
por: Makishima, Hideki, et al.
Publicado: (2013)

Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report
por: Deng, Lai-Jun, et al.
Publicado: (2023)

P1001: DNMT3A/TET2/ASXL1 MUTATIONS DETERMINE THROMBOTIC RISK IN POLYCYTHAEMIA VERA
por: Segura Diaz, A., et al.
Publicado: (2022)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
por: Patnaik, M M, et al.
Publicado: (2016)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

SETBP1 dysregulation in congenital disorders and myeloid neoplasms
por: Coccaro, Nicoletta, et al.
Publicado: (2017)

The Role of SETBP1 in Gastric Cancer: Friend or Foe
por: Fang, Fujin, et al.
Publicado: (2022)

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bu2m5982k82r51kis8fm67n5o3